Experience

Quanta BioDesign, Ltd.

• United States
• Chemical Manufacturing
• 1 - 100 Employee

• Chief Technology Development Officer

  • Jan 2020 - Present

  Responsible for leveraging Quanta BioDesign’s unique SuperHydrophilc dPEG® technology to develop novel new products for life sciences applications. The biocompatibility of dPEG reagents creates a platform for rethinking and redesigning the way traditional bioscience reagents are made. For instance, when used to modify, label, or conjugate biomolecules dPEG provides exciting new properties that make them superior to traditional reagents. dPEG crosslinkers can create antibody conjugates with higher specificity, greater water solubility, better stability, and lower background in assays and detection applications. dPEG modification reagents can be used to eliminate protein aggregation and increase stability of labeled proteins. They also can be used to modulate pharmacokinetics (PK), biodistribution (BD), and the route of excretion for conjugates used in vivo. The use of dPEG reagents to design new bioreagents provides a platform for creating unique life science products with significantly better performance.



Greg T Hermanson, Inc., Bioscience Consulting Services

• President

  • Apr 2015 - Present

  Consulting services with a focus in bioconjugation, surface modification, ligand immobilization, purification, detection, protein chemistry, fluorescent dyes, and assay development related to research, diagnostics, and therapeutic applications. Also provides services related to intellectual property (IP), licensing and technology acquisition, negotiations, and patent filing. Consulting services with a focus in bioconjugation, surface modification, ligand immobilization, purification, detection, protein chemistry, fluorescent dyes, and assay development related to research, diagnostics, and therapeutic applications. Also provides services related to intellectual property (IP), licensing and technology acquisition, negotiations, and patent filing.



Aurora Microarray Solutions, Inc

• Chief Technology Officer and Principal

  • Apr 2015 - Jan 2020

  Leader of technology management and diagnostic product development for global disease and autoimmune testing using advanced microarray platforms. Leader of technology management and diagnostic product development for global disease and autoimmune testing using advanced microarray platforms.



Thermo Fisher Scientific

• United States
• Biotechnology Research
• 700 & Above Employee

• Director of Technology and Business Development

  • 2006 - Mar 2015

  Technology management, assessment and acquisition, including licensing, intellectual property, patent filings, negotiations, collaborations, and partnerships. Worked closely with R&D to invent and develop new products in the proteomics, detection, assay, sample prep, purification, and mass spectrometry areas. Technology management, assessment and acquisition, including licensing, intellectual property, patent filings, negotiations, collaborations, and partnerships. Worked closely with R&D to invent and develop new products in the proteomics, detection, assay, sample prep, purification, and mass spectrometry areas.



Pierce Biotechnology, Inc

• Director of Technology

  • 2002 - 2006



Pierce Biotechnology, Inc.

• Director of R&D

  • Jan 2000 - 2002